The Manila Times

Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical O…

European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion ...